Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer

Stopped early · Not applicable

Conditions studied: Cervical Cancer

In brief

Rationale: Computer systems that allow doctors to create a 3 dimensional (3-D) picture of the tumor may help in planning radiation therapy and may result in more tumor cells being killed. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as cisplatin, may make tumor cells more sensitive to radiation therapy.

Key facts

Study ID

NCT01016561

Run by

Abramson Cancer Center at Penn Medicine

People needed

12

Starts

2009-07-01

Expected to finish

2016-12-01

Last updated by the study team

2021-05-05

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have histologically confirmed squamous cell, adenosquamous or adenocarcinoma of the cervix
• Subjects must have non-metastatic FIGO Stage Ia-IVa cervical cancer
• Claustrophobic subjects must agree to be sedated during MRI procedures
• ECOG performance status of 0-2

You may not qualify if…

• Subjects with an inability to tolerate MR imaging
• Subjects who have had prior surgery for treatment of disease other than exploratory laparotomy or biopsy
• Study subjects who have contraindication to MRI scanning such as but not limited to subjects with pacemakers, metal fragments in the eye or certain metallic implants
• Women of childbearing potential who have a positive result on screening serum pregnancy test

Where it is running

• Abramson Cancer Center of the Unviersity of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.